Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration
- Determine the efficacy, of imatinib mesylate, in terms of achieving a therapeutic
tumor:plasma concentration ratio, in patients with primary malignant glioma.
- Correlate tumor grade (low vs high) and/or tumor enhancement on MRI with tumor
concentration of this drug in these patients.,
OUTLINE: Patients receive oral imatinib mesylate once daily for 7-12 days. Patients then
undergo surgical resection.
Blood and tissue samples are collected at the time of surgery and analyzed for imatinib
After completion of study treatment, patients are followed for 7 days.
PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Tumor:plasma concentration ratio of imatinib mesylate
Stuart A. Grossman, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|